This is the authors' abstract. We don't add key points for this paper.
Concurrent chemoradiotherapy (CCRT) is the standard treatment option for unresectable locally advanced nonsmall- cell lung cancer (LA-NSCLC) (1). Radiotherapy with a dose of 60–66 Gy and platinum-based doublet chemotherapy are commonly used in CCRT. However, outcomes with the standard treatment are not satisfying with a median survival of approximately 20 months. Both locoregional tumor recurrence and distant metastasis are potential obstacles in the treatment of LA-NSCLC.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yukinori Matsuo (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: